This medicine is now known as Angiotensin 1-7.
On 20 June 2017, orphan designation (EU/3/17/1879) was granted by the European Commission to Envigo Pharma Consulting Limited, United Kingdom, for Asp-Arg-Val-Tyr-Ile-His-Pro (also known as TXA127) for the treatment of epidermolysis bullosa.
The sponsorship was transferred to Envigo CRS S.A., Spain, in April 2019.
The sponsorship was transferred to Rapport Global Strategic Services Ireland Limited in January 2020.
Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7)
|Disease / condition||
Treatment of epidermolysis bullosa
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.